Drug profile · INN
omadacycline tosylate
NUZYRA
omadacycline tosylate (NUZYRA) is a bacterial 70s ribosome inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — omadacycline tosylate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
omadacycline tosylate (NUZYRA) is a bacterial 70s ribosome inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial 70S ribosome inhibitor
Primary target: Bacterial 70S ribosome
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is omadacycline tosylate?
omadacycline tosylate (NUZYRA) is a bacterial 70s ribosome inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for omadacycline tosylate?
NUZYRA is a marketed brand name for omadacycline tosylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of omadacycline tosylate?
omadacycline tosylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.